Wichit Arpornwirat - Concepedia

Concepedia

Author

Wichit Arpornwirat

National Cancer Institute of Thailand

Also Known As

W Arpornwirat, W. Arpornwirat, Wichit Arpornwirat

29

Publications

1.2K

Citations

10

H-Index

31

Concepts

All Affiliations

National Cancer Institute of Thailand GlaxoSmithKline (United States)Ulsan College Asan Medical Center University of Vermont

WA

About

Wichit Arpornwirat is an author at National Cancer Institute of Thailand specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	983
2	Health Sciences	3	3	885
3	Immunology	2	2	43
4	Public Health	1	1	16
5	Epidemiology	1	1	16

Wichit Arpornwirat

×

10

Publications

1.2K

Citations

10

H-Index

	Year	Citations
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Sandra M. Swain, David Miles, Sung‐Bae Kim, The Lancet Oncology End-of-study ResultsBreast OncologyMedicineClinical TrialsPathology	2020	854
Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer Zhongzhen Guan, Binghe Xu, Michelle DeSilvio, Journal of Clinical Oncology	2013	139
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations Natasha B. Leighl, Naiyer A. Rizvi, Lopes Gilberto de Lima, Clinical Lung Cancer Non–small-cell Lung CancerOncologyMedicinePharmacotherapyAnti-cancer Agent	2016	39
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine Gerald Goh, Ramona Schmid, Kelly Guiver, PLoS Medicine	2016	36
Phase 2 trial results with the novel neurokinin‐1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy Wichit Arpornwirat, István Albert, Vincent Hansen, Cancer	2009	29
Serum p53 antibodies in correlation to other biological parameters of breast cancer Suleeporn Sangrajrang, Wichit Arpornwirat, A Cheirsilpa, Cancer Detection and Prevention Serum P53 AntibodiesOther Biological ParametersBreast OncologyMedicineImmunology	2003	28
Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC) Steven M. Grunberg, Zeba Aziz, Abbas Shaharyar, Journal of Clinical Oncology Emetogenic ChemotherapyCasopitant RegimensReceptor AntagonistPhase Iii ResultsPharmacotherapy	2008	20
Personal use of hair dyes--increased risk of non-Hodgkin's lymphoma in Thailand. Suleeporn Sangrajrang, Hélène Renard, Thiravud Kuhaprema, PubMed Lymphoid NeoplasiaEpidemiologyHair DyesCancer EpidemiologyCancer Risk	2011	16
Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC) Wichit Arpornwirat, István Albert, Vincent Hansen, Journal of Clinical Oncology ImmunologyPharmacotherapyImmunotherapeuticsPre-clinical PharmacologyMolecular Pharmacology	2006	15
Abstract P3-14-24: Overall Survival Benefit Observed with Lapatinib (L) Plus Paclitaxel (P) as First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer (MBC) Z-Z Guan, BH Xu, Wichit Arpornwirat, Cancer Research First-line TherapyBreast OncologyMedicinePharmacologyClinical Trials	2010	11

Page 1